ArticleBMC cancer2025
BALs are prognostic biomarkers and correlate with malignant behaviors in breast cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe B-aggressive lymphoma (BAL) proteins, including BAL1, BAL2, and BAL3, constitute a conserved protein family characterized by their N-terminal macro domains and putative C-terminal poly (ADP-ribose) polymerase (PARP) active site. Dysregulation of BALs has been closely associated with the progression of various cancers. However, there is limited understanding of their precise expression profile, prognostic significance, and role in breast cancer (BC).
methodsThe expression patterns of BALs were evaluated utilizing multiple databases, including Ualcan, Gene Set Cancer Analysis (GSCA), Search Tool for the Retrieval of Interacting Genes/Proteins (STRING), and Gene Expression Profiling Interactive Analysis (GEPIA). The prognostic significance of BALs was assessed via Kaplan-Meier plotter analysis. Furthermore, the potential mechanisms underlying the contribution of BC progression were predicted through GO and KEGG pathway enrichment analysis. Additionally, the effect of BALs on the malignant behaviors of BC cells was determined using CCK-8 assay, Transwell assay, and TUNEL assay.
resultsThe data revealed that the expression levels of both BAL1 and BAL2 were upregulated in BC, whereas no significant change was observed for BAL3. Survival analysis demonstrated a strong association between the overexpression of both BAL1 and BAL2 and favorable prognosis in patients with various subtypes of BC, including estrogen receptor (ER)-positive, ER-negative, Basal, luminal B, HER2-, and HER2 + subtypes. Additionally, the knockdown of BAL1 and BAL2 inhibited the proliferation and migration of BC cells while facilitating apoptosis.
conclusionsThese findings suggest that both BAL1 and BAL2 hold great potential as significant prognostic biomarkers and therapeutic targets for patients with BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.